ADVI Health’s Post

Did you know that many of our state trackers are updated regularly to reflect the latest state activity on some of today's toughest health policy challenges? Explore some of our recently updated trackers using the links below: 💊 State Legislation to Lower Prescription Drug Costs: https://loom.ly/GqUjZbg 💰 State Legislation to Lower Health System Costs: https://loom.ly/oybUuwI 🏥 Health Care Payment and Delivery System Transformation: https://loom.ly/7j4N4x8 🍼 State Efforts to Extend Medicaid Postpartum Coverage: https://loom.ly/_No7C7A

Our state trackers — interactive maps and charts that highlight what states are doing on a specific policy topic — provide a glimpse into how states are tackling today’s biggest health policy challenges. Check out one of our recently updated trackers using the links below — or explore all our trackers: https://loom.ly/ZHWKq-U ➡️ State Legislation to Lower Prescription Drug Costs: https://loom.ly/GqUjZbg ➡️ State Legislation to Address Health System Costs: https://loom.ly/c-35YcE ➡️ State Opioid Settlement Spending Decisions: https://loom.ly/Sb8bDM8 ➡️ State Efforts to Extend Medicaid Postpartum Coverage: https://loom.ly/_No7C7A

A News Alert from 340B Report: 340B Coalition Conference Keynote: Program Faces ‘Progress Amid Challenges’ - https://lnkd.in/ecAHeNJa To get full access to 340B Report news reporting and analysis, visit https://lnkd.in/gJd7qNyg #340B #pharmacy #drugpricing #hospitals #hospitalpharmacy

Now is the time to have your voice heard! As leaders in the Pharma space, we play an important role in the regulations that shape the future of our industry. I believe that accountability plays a crucial role in leadership. It is both the mechanism through which we build trust and a necessary function of the systems that maintain fair markets. When we meaningfully contribute to processes like this, we are sending signals about public-private cooperation that sets the tone for innovations and compliance standards for years to come. What do you believe can be added to this discussion? Leave a comment down below! #Pharma #Regualtion #Compliance #Accoutability

Thanks to Endpoints News for interviewing me and the always brilliant Leslie Isenegger, MPP about healthcare policy in last night's State of the Union. The speech was light on healthcare overall, which was surprising as the IRA drug pricing provisions is a signature accomplishment for the administration and targets a key voting block. It could be because these provisions are difficult to message to voters, as cost savings for seniors, if they see them at all, are years away. It's reminiscent of the challenge the Obama Administration faced following the passage of the Affordable Care Act. While a monumental accomplishment to get any healthcare legislation passed in this environment, the impact took years for voters to feel the effect. Policy changes to the most complex healthcare system in the world are hard, incremental and often boring. The Biden administration's singular focus on "Big Pharma" doesn't necessarily impact the convoluted system that determines drug prices, but it's good politics in an election year where quick wins are key. https://lnkd.in/gMXb7UMX

Check out Axinn partner Chad Landmon's insights in the Law360 article, "For Medicare Drug Cost Suits, Final Price Could Be Key." Read more at the link below. #axinn #medicare

#Payer organizations face fragmentation between medical and drug benefit teams, especially with the rise of #specialtydrugs. Check out this Wolters Kluwer Expert Insight to discover how evidence-based solutions and internal alignment can enhance efficiencies and policy development. https://gag.gl/ziLBpt #HealthcareInnovation

Last week I had the privilege of being invited to speak to the Oregon Senate Health Care Committee about the 340B program. The point I continue to make is that the program is worth very little if not for our outrageous drug prices. Whether 340B is the right way to fund the safety net is a worthy discussion...but for now, it's one of the most important mechanisms we have and one of the few things that punishes out of control growth in drug prices. #340B #pharmacy #340Bprogram #healthcare 340B Health Nelco Advisory https://lnkd.in/gV4pcP6X

#Payer organizations face fragmentation between medical and drug benefit teams, especially with the rise of #specialtydrugs. Discover how evidence-based solutions and internal alignment can enhance efficiencies and policy development. https://ow.ly/e7Kh50SSjRS #HealthcareInnovation

#ICYMI: We Work For Health's Executive Director explained why the results of the first #Medicare drug price caps mark the latest troubling chapter in #IRA missteps. Read more here: https://lnkd.in/gEWNxR_J